Equity awards for Taysha (TSHA) director Alison S. Long detailed
Rhea-AI Filing Summary
Taysha Gene Therapies director Alison S. Long reported equity compensation awards. She received 21,335 shares of Common Stock as a restricted stock unit (RSU) award that will vest on the earlier of June 1, 2027 or the next annual stockholders meeting, contingent on her continued board service.
She was also granted stock options covering 42,671 shares of Common Stock at an exercise price of $5.97 per share, expiring on June 1, 2036. Following these awards, she directly holds 127,178 shares of Common Stock and 42,671 stock options.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 21,335 shares
Net Buy
2 txns
Insider
Long Alison S
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 42,671 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 21,335 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 42,671 shares (Direct);
Common Stock — 127,178 shares (Direct)
Footnotes (2)
- F1. Represents a restricted stock unit ("RSU") award. The RSUs will vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date.
- F2. The shares vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date.
Key Figures
RSU award: 21,335 shares
Stock options granted: 42,671 options
Option exercise price: $5.97 per share
+1 more
4 metrics
RSU award
21,335 shares
Restricted stock units vesting by June 1, 2027 or next annual meeting
Stock options granted
42,671 options
Right to buy common stock, vesting on same schedule as RSUs
Option exercise price
$5.97 per share
Exercise price for 42,671 stock options expiring June 1, 2036
Shares held after transaction
127,178 shares
Total common stock directly owned after reported awards
Key Terms
restricted stock unit ("RSU"), Stock Option (right to buy), annual stockholders meeting, exercise price
4 terms
restricted stock unit ("RSU") financial
"Represents a restricted stock unit ("RSU") award."
Stock Option (right to buy) financial
"Stock Option (right to buy) with an exercise price of $5.9700."
annual stockholders meeting financial
"vest on the earlier of June 1, 2027 or the next annual stockholders meeting"
exercise price financial
"conversion_or_exercise_price": "5.9700""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did Taysha Gene Therapies (TSHA) director Alison S. Long report on this Form 4?
Alison S. Long reported equity compensation awards from Taysha Gene Therapies, including a grant of RSUs and stock options. These awards increase her direct ownership in the company’s common stock and reflect routine director compensation rather than open‑market buying or selling activity.
How many RSUs did Alison S. Long receive from Taysha Gene Therapies (TSHA)?
She received an award of 21,335 restricted stock units (RSUs). These RSUs represent the right to receive an equivalent number of Taysha Gene Therapies common shares, subject to vesting conditions tied to her continued service on the company’s board of directors.
When do Alison S. Long’s RSUs and options in Taysha Gene Therapies (TSHA) vest?
Both the RSU award and the underlying shares for the stock options vest on the earlier of June 1, 2027 or the next annual stockholders meeting. Vesting is conditioned on Alison S. Long continuing to serve as a director through the applicable vesting date.
What are the terms of the stock options granted to Alison S. Long by Taysha Gene Therapies (TSHA)?
She received stock options for 42,671 shares of common stock with an exercise price of $5.97 per share. These options expire on June 1, 2036 and vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to continued board service.
Is Alison S. Long’s Form 4 for Taysha Gene Therapies (TSHA) an open-market purchase or sale?
No, the Form 4 reflects equity compensation, not open‑market trades. The transactions are coded as grants or awards, meaning the RSUs and stock options were issued by Taysha Gene Therapies as part of director compensation rather than being bought or sold on the market.